Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech sued over satraplatin delay
GPC Biotech withdrew satraplatin from the Fast Track approval process in the US after the FDA said that it would require overall survival data from a trial that
GPC Biotech withdrew satraplatin from the Fast Track approval process in the US after the FDA said that it would require overall survival data from a trial that
Angiogenesis inhibitors that block a tumor’s development of an independent blood supply have been touted as effective cancer fighters that result in fewer side effects than traditional chemotherapy.
The company’s restructuring plan involves cutting 46 staff from a current total of 316 employees, or approximately 15% of the total workforce. All affected staff are based in
Exelixis confirmed that it has agreed to the request from GSK to initiate its review of XL880 before the compound reaches proof-of-concept. Exelixis expects to deliver the appropriate
In the extension phase of the study, 12 patients were treated at the highest dose, 480mg/m2/day, as determined in first portion of the trial. The phase I/II clinical
The preclinical in vitro research conducted by Alfacell and researchers at New York Medical College demonstrated that treatment of cells in cultures with Onconase reduced intracellular oxidative stress
Researchers from the University of Leeds have discovered that one of the body’s naturally occurring proteins is preventing 57 genes from operating normally in the brains of Huntington’s
The trials involved priming an immune response with three doses of a plasmid DNA (pDNA) vaccine over a two-month period, based on Vical’s proprietary DNA technology, and boosting
Risperdal (risperidone) is already indicated in adults for the treatment of schizophrenia, manic symptoms of acute manic or mixed episodes associated with bipolar I disorder, and for the
The designation has been given to Marqibo for the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia (ALL) in second relapse or who have failed two lines of